Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(E)-Daporinad (FK866) 是一种烟酰胺磷酸核糖基转移酶的小分子抑制剂,具有潜在的抗肿瘤和抗血管生成活性,IC50为 0.09 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 238 | 现货 | ||
2 mg | ¥ 338 | 现货 | ||
5 mg | ¥ 549 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,870 | 现货 | ||
50 mg | ¥ 2,750 | 现货 | ||
100 mg | ¥ 3,830 | 现货 | ||
500 mg | ¥ 8,490 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 591 | 现货 |
产品描述 | (E)-Daporinad (FK866) is a small molecule inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase), with potential antineoplastic and antiangiogenic activities. |
靶点活性 | NMPRTase:0.4 nM(Ki) |
体外活性 | 对于携带CIA的小鼠, APO866(0.12 mg/kg)可以改善关节破坏和白细胞浸润.C.B.-17 SCID小鼠的人急性髓细胞白血病,淋巴母细胞淋巴瘤和白血病的异种移植模型中,腹腔注射APO866(20 mg/kg ),能够抑制肿瘤生长. |
体内活性 | 在多种血液恶性肿瘤细胞中,APO866(0.09-27 nM)通过诱导胞内NAD 和 ATP 的损耗,能够以剂量依赖的方式诱导产生细胞毒性活性。在HFFF2细胞内, APO866(10 nM)能够抑制前B细胞克隆增强因子诱导的MMP-3, CCL2和CXCL8 的分泌。 |
激酶实验 | High Throughput Screening: FITC-MBM1 at 15 nM and menin at 150 nM in the FP buffer are mixed and incubated for 1h in the dark at room temperature. For point screening, the 0.2 μL of each compound (20 μM final concentration, 1% DMSO) is added to 20 μL of the aliquot of the protein-peptide mixture and incubated on 384-well plates in the dark at room temperature for 1h. In confirmation screening, the serial dilution plates with compounds in DMSO are prepared and used to titrate the menin-FITC-MBM1 complex. Change in fluorescence polarization is monitored at 525 nm after excitations at 495 nm using the PHERAstar microplate reader (BMG) and applied to determine IC50 values with the Origin 7.0 program. |
细胞实验 | For MTT assays, 0.5 × 106 cells/mL is plated in triplicate on 96-well plates. APO866 (0.01 nM-100 nM) is added in 50 μL of culture medium, with culture medium alone serving as control. After 72 or 96 hours of incubation, 15 μL of dye solution is added to each well and cells are incubated for an additional 4 hours. Stop solution (100 μL/well) is added for 1 hour and the absorbance is read at 570 nm on a spectrophotometer. For trypan blue dye exclusion staining, 0.5 × 105 cells/well is grown in 6-well plates with 1 mL media in the absence or presence of APO866 for 96 hours. Cells from each sample are incubated with 10 μL trypan blue solution (at a 1:1 ratio [vol/vol] for 1 minute). Cell survival is determined by calculating proportion of live (unstained) cells. (Only for Reference) |
别名 | Daporinad, (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE, APO866, FK866, 达珀利奈 |
分子量 | 391.51 |
分子式 | C24H29N3O2 |
CAS No. | 658084-64-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 72 mg/mL (183.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 2.5542 mL | 12.7711 mL | 25.5421 mL | 63.8553 mL |
5 mM | 0.5108 mL | 2.5542 mL | 5.1084 mL | 12.7711 mL | |
10 mM | 0.2554 mL | 1.2771 mL | 2.5542 mL | 6.3855 mL | |
20 mM | 0.1277 mL | 0.6386 mL | 1.2771 mL | 3.1928 mL | |
50 mM | 0.0511 mL | 0.2554 mL | 0.5108 mL | 1.2771 mL | |
100 mM | 0.0255 mL | 0.1277 mL | 0.2554 mL | 0.6386 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(E)-Daporinad 658084-64-1 Autophagy Metabolism NAMPT Transferase Daporinad inhibit Visfatin (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE (E) Daporinad FK 866 Nicotinamide phosphoribosyl transferase PBEF APO866 FK866 APO 866 Inhibitor Pre-B cell colony enhancing factor APO-866 达珀利奈 (E)Daporinad FK-866 inhibitor